Wesley Self

Wesley Self, MD, MPH
October 17, 2023

How biostatistics saves lives: the Vanderbilt experience

Biostatisticians at VUMC have played a pivotal role in the redesign of clinical trials that rigorously and rapidly determine the effectiveness of life-saving treatments for acutely ill patients.

By Bill Snyder
August 9, 2023

VUMC receives $51 million in NIH grants to improve efficiency of conducting clinical trials across the US

Vanderbilt researchers have been awarded two five-year federal grants totaling $51 million to harness new and existing approaches for boosting recruitment and removing roadblocks to the efficiency of conducting clinical trials throughout the country.

By Bill Snyder
From left, Frank Harrell Jr., PhD, Paul Harris, PhD, Wesley Self, MD, James Chappell, MD, PhD, Gordon Bernard, MD, Jana Shirey-Rice, PhD, and Jillian Rhoads, PhD, play key roles in a national effort to advance the understanding and treatment of acute respiratory distress syndrome, pneumonia and sepsis.
May 4, 2023

VUMC to coordinate national effort to reduce ARDS, pneumonia, sepsis

Vanderbilt University Medical Center has received a $31.6 million federal grant to lead a national effort to better understand acute respiratory distress syndrome, pneumonia and sepsis.

By Bill Snyder
Wesley Self, MD, MPH
April 11, 2023

VUMC-led trial shows two investigational drugs are ineffective for treating severe COVID-19

A Vanderbilt-led study evaluating two investigational drugs to treat severe COVID-19 demonstrated that neither drug was effective.

By Nancy Humphrey
February 9, 2023

American Society for Clinical Investigation honors 10 Vanderbilt physicians

By Bill Snyder
Wesley Self, MD, MPH
February 2, 2023

Study of two sepsis interventions finds identical outcomes

Vanderbilt University Medical Center had a leading role in a large national study designed to compare two early interventions in the treatment of patients with sepsis, the body’s severe response to an uncontrolled infection.

By Nancy Humphrey
January 5, 2023

VUMC-led COVID-19 clinical trial platform goes international

The ACTIV-4 Host Tissue clinical trial platform, which is designed to investigate therapies targeting the host tissue response to COVID-19 to mitigate lung injury, is now being expanded internationally.
By Bill Snyder
December 16, 2022

Bivalent booster vaccine effective in preventing COVID-19 hospitalization in older adults

The new bivalent mRNA COVID-19 booster vaccines that began being used in September are beneficial in preventing COVID-19-associated hospitalization in persons 65 and over.
By Craig Boerner
December 16, 2022

VUMC Announces VICTR Leadership Transition

By Bill Snyder
September 22, 2022

Self named co-principal investigator of Vanderbilt’s Clinical and Translational Science Award

Wesley Self, MD, MPH, a physician-scientist at Vanderbilt University Medical Center, has been named co-principal investigator (co-PI) of Vanderbilt’s Clinical and Translational Science Award (CTSA).  
By Bill Snyder
July 7, 2022

Convalescent plasma doesn’t help severely ill COVID patients: study

A Vanderbilt clinical trial shows that convalescent plasma, widely given to severely ill patients hospitalized with COVID-19 during the pandemic, does not improve their ability to survive or recover
By Nancy Humphrey
April 13, 2022

Additional COVID vaccine helps protect transplant patients

Additional booster doses of vaccine against COVID-19 are particularly important for those who are immunosuppressed, namely those who have had solid organ transplants, a new study shows.
By Nancy Humphrey
February 9, 2022

Vanderbilt and CDC research shows third vaccine dose key to preventing omicron hospitalization

Vanderbilt research shows that two doses of an mRNA COVID-19 vaccine result in lower effectiveness for preventing hospitalization for the omicron variant than previous variants. However, importantly, a third (“booster”) vaccine dose significantly improves protection against omicron hospitalization up to 86%.
By Kristin Smart
1 2 3